<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443805</url>
  </required_header>
  <id_info>
    <org_study_id>SL75.14</org_study_id>
    <nct_id>NCT02443805</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes Greer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stallergenes Greer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to assess the efficacy and safety of 12 months of treatment
      with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with
      HDM-associated allergic rhinitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a randomized, double-blind, placebo-controlled, phase III study with 2
      parallel arms in adults and adolescents with HDM-associated allergic rhinitis (AR) for at
      least one year.

      The primary objective was to assess the efficacy of STG320 sublingual tablets at a daily
      dosage of 300 IR when administered for 12 months to adults and adolescents with
      HDM-associated AR. The primary efficacy variable was the average Total Combined Score.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2015</start_date>
  <completion_date type="Actual">June 25, 2018</completion_date>
  <primary_completion_date type="Actual">June 25, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Combined Score</measure>
    <time_frame>12 months</time_frame>
    <description>Average Total Combined Score (TCS), calculated for each patient as the average of the non-missing daily TCSs during the primary evaluation period. The daily TCS (scale 0-15) was the sum of the patient's daily Rhinitis Total Symptom Score (RTSS, scale 0-12) and daily Rescue Medication Score (RMS, scale 0-3). Lower is better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Rhinitis Total Symptom Score (RTSS)</measure>
    <time_frame>12 months</time_frame>
    <description>Average RTSS during the primary evaluation period. The daily Total Symptom Scores (RTSS) was the sum of the 4 rhinitis symptom scores: sneezing, rhinorrhoea, nasal pruritus and nasal congestion, each graded on a 4-point scale (0-3; 0: absent, 1: mild, 2: moderate, 3: severe).
It ranges from 0 to 12. Lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Rescue Medication Score (RMS)</measure>
    <time_frame>12 months</time_frame>
    <description>Average RMS during the primary evaluation period. Rescue Medication Score (RMS) ; range 0-3, lower is better.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1607</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <condition>House Dust Mite Allergy</condition>
  <arm_group>
    <arm_group_label>300 IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 IR tablet of HDM Allergen Extracts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>300 IR</intervention_name>
    <description>300 IR tablet of HDM Allergen Extracts</description>
    <arm_group_label>300 IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patients with HDM-associated allergic rhinitis (AR) for at least 1 year

          -  Patients sensitized to D. pteronyssinus (D. pte) and/or D. farinae (D. far) defined on
             skin prick test and HDM-specific serum IgE

        Main Exclusion Criteria:

          -  A history of rhinitis, rhinoconjunctivitis or asthma to allergens other than HDM,
             likely to result in rhinitis symptoms during the evaluation periods

          -  Partly controlled or uncontrolled asthma

          -  Controlled asthma requiring controller treatment(s) consistent with GINA 2014
             treatment Steps 3 to 5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Demoly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Arnaud de Villeneuve, Montpellier, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Casale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South of Florida, Tampa, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <results_first_submitted>August 29, 2019</results_first_submitted>
  <results_first_submitted_qc>September 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2019</results_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02443805/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02443805/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted between 29 September 2015 (first patient, first visit) and 25 June 2018 (last patient, last visit).</recruitment_details>
      <pre_assignment_details>2,174 (50.9%) and 486 (11.4%) patients were excluded before and during the placebo run-in period, respectively. The main reason for screen failures at these two stages was a failure to meet randomization criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>300 IR</title>
          <description>300 IR tablet of HDM Allergen Extracts</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="802"/>
                <participants group_id="P2" count="805"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="589"/>
                <participants group_id="P2" count="678"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by parent/guardian</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Any other reason not above-mentioned</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set (FAS) included all randomized patients who received at least one dose of the IP of treatment period and had at least one primary efficacy evaluation during the overall treatment period.</population>
      <group_list>
        <group group_id="B1">
          <title>300 IR</title>
          <description>300 IR tablet of HDM Allergen Extracts</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="711"/>
            <count group_id="B2" value="765"/>
            <count group_id="B3" value="1476"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="13.07"/>
                    <measurement group_id="B2" value="29.6" spread="12.58"/>
                    <measurement group_id="B3" value="29.6" spread="12.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="360"/>
                    <measurement group_id="B2" value="396"/>
                    <measurement group_id="B3" value="756"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                    <measurement group_id="B2" value="369"/>
                    <measurement group_id="B3" value="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="660"/>
                    <measurement group_id="B2" value="719"/>
                    <measurement group_id="B3" value="1379"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="660"/>
                    <measurement group_id="B2" value="701"/>
                    <measurement group_id="B3" value="1361"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="453"/>
                    <measurement group_id="B2" value="477"/>
                    <measurement group_id="B3" value="930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Combined Score</title>
        <description>Average Total Combined Score (TCS), calculated for each patient as the average of the non-missing daily TCSs during the primary evaluation period. The daily TCS (scale 0-15) was the sum of the patient's daily Rhinitis Total Symptom Score (RTSS, scale 0-12) and daily Rescue Medication Score (RMS, scale 0-3). Lower is better.</description>
        <time_frame>12 months</time_frame>
        <population>The FAS included all randomized patients (pts) who received at least one dose of the IP of treatment period and had at least one primary efficacy evaluation during the overall treatment period: 1,476 pts. Among these pts, only those with efficacy evaluation during the primary evaluation period were included in the primary analysis: 1,262 pts.</population>
        <group_list>
          <group group_id="O1">
            <title>300 IR</title>
            <description>300 IR tablet of HDM Allergen Extracts</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Total Combined Score</title>
          <description>Average Total Combined Score (TCS), calculated for each patient as the average of the non-missing daily TCSs during the primary evaluation period. The daily TCS (scale 0-15) was the sum of the patient's daily Rhinitis Total Symptom Score (RTSS, scale 0-12) and daily Rescue Medication Score (RMS, scale 0-3). Lower is better.</description>
          <population>The FAS included all randomized patients (pts) who received at least one dose of the IP of treatment period and had at least one primary efficacy evaluation during the overall treatment period: 1,476 pts. Among these pts, only those with efficacy evaluation during the primary evaluation period were included in the primary analysis: 1,262 pts.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.62" lower_limit="3.33" upper_limit="3.92"/>
                    <measurement group_id="O2" value="4.35" lower_limit="4.06" upper_limit="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Source Model: Type III effects Covariates: Treatment group, Gender, Age Class, Sensitization Status, Asthma Status, Pooled Center, Baseline Average RTSS.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Rhinitis Total Symptom Score (RTSS)</title>
        <description>Average RTSS during the primary evaluation period. The daily Total Symptom Scores (RTSS) was the sum of the 4 rhinitis symptom scores: sneezing, rhinorrhoea, nasal pruritus and nasal congestion, each graded on a 4-point scale (0-3; 0: absent, 1: mild, 2: moderate, 3: severe).
It ranges from 0 to 12. Lower is better.</description>
        <time_frame>12 months</time_frame>
        <population>The FAS included all randomized patients (pts) who received at least one dose of the IP of treatment period and had at least one primary efficacy evaluation during the overall treatment period: 1,476 pts. Among these pts, only those with efficacy evaluation during the primary evaluation period were included in the secondary analysis: 1,262 pts.</population>
        <group_list>
          <group group_id="O1">
            <title>300 IR</title>
            <description>300 IR tablet of HDM Allergen Extracts</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Average Rhinitis Total Symptom Score (RTSS)</title>
          <description>Average RTSS during the primary evaluation period. The daily Total Symptom Scores (RTSS) was the sum of the 4 rhinitis symptom scores: sneezing, rhinorrhoea, nasal pruritus and nasal congestion, each graded on a 4-point scale (0-3; 0: absent, 1: mild, 2: moderate, 3: severe).
It ranges from 0 to 12. Lower is better.</description>
          <population>The FAS included all randomized patients (pts) who received at least one dose of the IP of treatment period and had at least one primary efficacy evaluation during the overall treatment period: 1,476 pts. Among these pts, only those with efficacy evaluation during the primary evaluation period were included in the secondary analysis: 1,262 pts.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" lower_limit="2.89" upper_limit="3.43"/>
                    <measurement group_id="O2" value="3.79" lower_limit="3.53" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Rescue Medication Score (RMS)</title>
        <description>Average RMS during the primary evaluation period. Rescue Medication Score (RMS) ; range 0-3, lower is better.</description>
        <time_frame>12 months</time_frame>
        <population>The FAS included all randomized patients (pts) who received at least one dose of the IP of treatment period and had at least one primary efficacy evaluation during the overall treatment period: 1,476 pts. Among these pts, only those with efficacy evaluation during the primary evaluation period were included in the secondary analysis: 1,262 pts.</population>
        <group_list>
          <group group_id="O1">
            <title>300 IR</title>
            <description>300 IR tablet of HDM Allergen Extracts</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Average Rescue Medication Score (RMS)</title>
          <description>Average RMS during the primary evaluation period. Rescue Medication Score (RMS) ; range 0-3, lower is better.</description>
          <population>The FAS included all randomized patients (pts) who received at least one dose of the IP of treatment period and had at least one primary efficacy evaluation during the overall treatment period: 1,476 pts. Among these pts, only those with efficacy evaluation during the primary evaluation period were included in the secondary analysis: 1,262 pts.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.17" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.30" lower_limit="0.26" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Safety variables were adverse events (AEs) monitored throughout the study and data from physical examinations and clinical laboratory assessments.
1,607 patients were randomized. 6 patients randomized by mistake did not receive any IP of the treatment period and were excluded from the Safety Set.
Accordingly, the Safety Set comprised 1,601 patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>300 IR</title>
          <description>300 IR tablet of HDM Allergen Extracts</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablet</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Chronic fatigue syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Tick-borne viral encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Plica syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngeal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="424" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Oedema mouth</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Lip oedema</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="800"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martine Le Gall, Director of Clinical Development</name_or_title>
      <organization>Stallergenes Greer</organization>
      <phone>+33 1 55 59 25 56</phone>
      <email>martine.legall@stallergenesgreer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

